NTLA
BEARISH
$14.94
Live
Intellia Therapeutics, Inc. · NASDAQ
Target $25.29
(+69.2%)
$6.8
52W Range
$28.25
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 16, 2026
Market cap
$1.76B
P/E
N/A
ROE
-53.5%
Profit margin
N/A
Debt/Equity
0.14
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
Intellia Therapeutics exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 1/9, indicating poor financial health and operational inefficiency. While the company maintains a strong liquidity position with a current ratio of 5.08 and low debt, it is plagued by massive operating losses (-428.86% margin) and a prohibitively high Price/Sales ratio of 26.08. Despite strong YoY revenue growth and positive analyst price targets, the combination of bearish insider selling and a long-term 5-year price decline of 78.8% suggests a high-risk speculative profile rather than a value investment.
Key Strengths
Strong short-term liquidity with a current ratio of 5.08
Robust YoY revenue growth of 78.80%
Low leverage with a Debt/Equity ratio of 0.14
Recent trend of beating earnings estimates (3 of last 4 quarters)
Significant analyst upside potential (Target $25.29 vs Current $14.94)
Key Risks
Extreme operational inefficiency with -428.86% operating margin
Severe fundamental health failure (Piotroski F-Score 1/9)
Prohibitively expensive valuation on a Price/Sales basis (26.08x)
Consistent insider selling by the CEO and other key officers
Negative long-term price performance (-78.8% over 5 years)
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
25
Weak
15
65
20
25
0
AI Verdict
Speculative/High Risk
Key drivers: Piotroski F-Score 1/9, High Revenue Growth, Bearish Insider Sentiment, Strong Liquidity
Confidence
90%
Value
15/100
Trades at a massive premium to revenue with no current earnings to support the valuation.
Positives
No standout positives identified.
Watchpoints
- P/S ratio of 26.08 is extreme
- No P/E or Graham Number due to lack of profitability
Future
65/100
Growth is strong, but monetization remains distant.
Positives
- 78.8% YoY Revenue growth
- Improving EPS trajectory
Watchpoints
- High cash burn rate
Past
20/100
Long-term destruction of shareholder value despite recent short-term volatility.
Positives
- 1Y return of +103%
Watchpoints
- 5Y return of -78.8%
- 3Y return of -61.9%
Health
25/100
Strong balance sheet liquidity prevents immediate distress, but operational health is failing.
Positives
- Current Ratio 5.08
- Low Debt/Equity 0.14
Watchpoints
- Piotroski F-Score 1/9
- Negative ROE and ROA
Dividend
0/100
Typical for early-stage biotech.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$14.94
Analyst Target
$25.29
Upside/Downside
+69.2%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for NTLA and closest competitors.
Updated 2026-04-15
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
NTLA
Intellia Therapeutics, Inc.
Primary
|
-78.8% | -61.9% | +103.0% | -42.4% | +11.7% | +7.7% |
|
INVA
Innoviva, Inc.
Peer
|
+103.6% | +101.2% | +39.0% | +37.0% | +6.0% | +3.4% |
|
ESTA
Establishment Labs Holdings Inc.
Peer
|
-10.1% | -12.1% | +127.1% | +54.6% | -10.2% | +5.6% |
|
OMCL
Omnicell, Inc.
Peer
|
-72.8% | -36.3% | +19.7% | +25.4% | +9.4% | +5.5% |
|
AZTA
Azenta, Inc.
Peer
|
-50.6% | -29.6% | -26.9% | +16.3% | +16.1% | +0.1% |
NTL
Intellia Therapeutics, Inc.
Primary
5Y
-78.8%
3Y
-61.9%
1Y
+103.0%
6M
-42.4%
1M
+11.7%
1W
+7.7%
INV
Innoviva, Inc.
Peer
5Y
+103.6%
3Y
+101.2%
1Y
+39.0%
6M
+37.0%
1M
+6.0%
1W
+3.4%
EST
Establishment Labs Holdings Inc.
Peer
5Y
-10.1%
3Y
-12.1%
1Y
+127.1%
6M
+54.6%
1M
-10.2%
1W
+5.6%
OMC
Omnicell, Inc.
Peer
5Y
-72.8%
3Y
-36.3%
1Y
+19.7%
6M
+25.4%
1M
+9.4%
1W
+5.5%
AZT
Azenta, Inc.
Peer
5Y
-50.6%
3Y
-29.6%
1Y
-26.9%
6M
+16.3%
1M
+16.1%
1W
+0.1%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-5.11
PEG Ratio
N/A
P/B Ratio
2.59
P/S Ratio
26.08
EV/Revenue
20.81
EV/EBITDA
-3.27
Market Cap
$1.76B
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-428.86%
Gross Margin
N/A
ROE
-53.48%
ROA
-27.11%
Growth
Revenue and earnings growth rates
Revenue Growth
+78.8%
Earnings Growth
N/A
Q/Q Revenue Growth
+78.79%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.14
Low debt
Current Ratio
5.08
Strong
Quick Ratio
4.42
Excellent
Cash/Share
$3.81
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Op. Margin
-428.9%
Net Margin
-416.2%
Total Assets
$0.8B
Liabilities
$0.2B
Equity
$0.7B
Debt/Equity
0.25x
Operating CF
$-0.1B
CapEx
$-0.0B
Free Cash Flow
$-0.1B
FCF Yield
100%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-02-26
$-0.83
+13.7% surprise
2025-11-06
$-0.92
+7.8% surprise
2025-08-07
$-0.98
+2.5% surprise
Healthcare Sector Comparison
Comparing NTLA against 421 companies in the Healthcare sector
(25 bullish, 134 neutral, 262 bearish)
Return on Equity (ROE)
-53.48%
This Stock
vs
-100.15%
Sector Avg
-46.6%
(Below Avg)
Debt to Equity
0.14
This Stock
vs
3.22
Sector Avg
-95.7%
(Less Debt)
Revenue Growth
78.8%
This Stock
vs
121.05%
Sector Avg
-34.9%
(Slower)
Current Ratio
5.08
This Stock
vs
4.55
Sector Avg
+11.7%
(Better)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
NTLA
Intellia Therapeutics, Inc.
|
BEARISH | $1.76B | - | -53.5% | -% | $14.94 | |
|
INVA
Innoviva, Inc.
|
BULLISH | $1.77B | 7.2 | 29.1% | 65.9% | $23.76 | Compare |
|
ESTA
Establishment Labs Holdings Inc.
|
BEARISH | $1.82B | - | -133.3% | -24.2% | $62.01 | Compare |
|
OMCL
Omnicell, Inc.
|
NEUTRAL | $1.71B | 938.25 | 0.2% | 0.2% | $37.53 | Compare |
|
AZTA
Azenta, Inc.
|
NEUTRAL | $1.84B | 77.02 | 1.4% | -9.4% | $40.05 | Compare |
NTLA
Intellia...
BEARISH
Mkt Cap
$1.8B
P/E
-
ROE
-53.5%
Price
$14.94
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-02 | BASTA JAMES EDMUND | General Counsel | Sale | 1,211 | $16,688 |
| 2026-03-02 | CLARK ELIANA | Chief Technology Officer | Sale | 607 | $8,364 |
| 2026-02-27 | LEONARD JOHN M | Chief Executive Officer | Stock Award | 156,400 | - |
| 2026-02-27 | BASTA JAMES EDMUND | General Counsel | Stock Award | 46,080 | - |
| 2026-02-27 | LEBWOHL DAVID | Officer | Stock Award | 9,943 | - |
| 2026-02-27 | DULAC EDWARD J III | Chief Financial Officer | Stock Award | 61,280 | - |
| 2026-02-27 | CLARK ELIANA | Chief Technology Officer | Stock Award | 7,353 | - |
| 2026-02-27 | DUBE MICHAEL P | Officer | Stock Award | 17,250 | - |
| 2026-02-27 | SCHULTES BIRGIT C PH.D. | Officer | Stock Award | 39,200 | - |
| 2026-01-05 | COHEN FREDERICK E. M.D. PH.D. | Director | Purchase | 150,000 | $1,402,500 |
| 2026-01-05 | LEONARD JOHN M | Chief Executive Officer | Sale | 34,146 | $314,485 |
| 2026-01-05 | BASTA JAMES EDMUND | General Counsel | Sale | 10,397 | $95,756 |
| 2026-01-05 | LEBWOHL DAVID | Officer | Sale | 11,903 | $109,627 |
| 2026-01-05 | DULAC EDWARD J III | Chief Financial Officer | Sale | 6,379 | $58,751 |
| 2026-01-05 | CLARK ELIANA | Chief Technology Officer | Sale | 9,515 | $87,633 |
BASTA JAMES EDMUND
General Counsel
2026-03-02
1,211 shares
·
$16,688
CLARK ELIANA
Chief Technology Officer
2026-03-02
607 shares
·
$8,364
LEONARD JOHN M
Chief Executive Officer
2026-02-27
156,400 shares
BASTA JAMES EDMUND
General Counsel
2026-02-27
46,080 shares
LEBWOHL DAVID
Officer
2026-02-27
9,943 shares
DULAC EDWARD J III
Chief Financial Officer
2026-02-27
61,280 shares
CLARK ELIANA
Chief Technology Officer
2026-02-27
7,353 shares
DUBE MICHAEL P
Officer
2026-02-27
17,250 shares
SCHULTES BIRGIT C PH.D.
Officer
2026-02-27
39,200 shares
COHEN FREDERICK E. M.D. PH.D.
Director
2026-01-05
150,000 shares
·
$1,402,500
LEONARD JOHN M
Chief Executive Officer
2026-01-05
34,146 shares
·
$314,485
BASTA JAMES EDMUND
General Counsel
2026-01-05
10,397 shares
·
$95,756
LEBWOHL DAVID
Officer
2026-01-05
11,903 shares
·
$109,627
DULAC EDWARD J III
Chief Financial Officer
2026-01-05
6,379 shares
·
$58,751
CLARK ELIANA
Chief Technology Officer
2026-01-05
9,515 shares
·
$87,633
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
21 analysts
Jones Trading
2026-03-04
Hold
Buy
Canaccord Genuity
2026-03-03
Buy
Buy
Leerink Partners
2026-03-03
Outperform
Outperform
RBC Capital
2026-03-03
Sector Perform
Sector Perform
Wells Fargo
2026-03-03
Equal-Weight
Equal-Weight
Citizens
2026-03-03
Market Outperform
Market Outperform
HC Wainwright & Co.
2026-03-03
Buy
Buy
Chardan Capital
2026-03-02
Buy
Buy
Chardan Capital
2026-02-27
Buy
Buy
HC Wainwright & Co.
2026-01-28
Buy
Buy
Past News Coverage
Recent headlines mentioning NTLA from our newsroom.
Newest → oldest
No matching news yet.